CAFI CONSUMER AUTOMOTIVE FIN INC

Consumer Automotive Finance, Inc. Announces Nationwide Teleconference as It Transitions to Fifty 1 Labs, Inc.

Consumer Automotive Finance, Inc. Announces Nationwide Teleconference as It Transitions to Fifty 1 Labs, Inc.

MELBOURNE, Fla., Feb. 27, 2025 (GLOBE NEWSWIRE) -- via IBN – Consumer Automotive Finance, Inc. (), soon to be rebranded as Fifty 1 Labs, Inc., a dynamic leader in the sports supplement, fitness equipment, and health and wellness sectors, is proud to announce a nationwide teleconference to be hosted on the XSpaces platform on March 12, 2025.

The teleconference will feature retired NFL star and company President Brandon Spikes, who will address shareholder questions and discuss the exciting roadmap for 2025 and beyond. This interactive session is designed to offer current and prospective shareholders an exclusive look into the strategic initiatives, innovative product developments, and forward-thinking vision that will shape the future of Fifty 1 Labs.

The Company recently announced the finalization of an agreement to retire 246 million of its issued and outstanding common shares. This transformative action, executed with precision by the company's management team, underscores an unwavering dedication to fortifying shareholder value and optimizing its capital structure as it continues to thrive on the OTC market.

"I am thrilled to engage directly with our valued shareholders as we unveil our plans for the coming year. Our commitment to innovation in sports supplements, fitness equipment, and overall health and wellness is stronger than ever, and I look forward to discussing how our evolving strategy will drive growth and success," said Brandon Spikes, President of Fifty 1 Labs.

Key highlights of the teleconference include:

  • Shareholder Q&A Session: An open forum for shareholders to get answers to questions and gain insights directly from leadership.
  • 2025 Roadmap Overview: Detailed discussion of upcoming strategic initiatives and growth opportunities.
  • Interactive Engagement: Participation via the XSpaces platform, offering a seamless experience for all attendees.

Fifty 1 Labs, Inc. invites all shareholders—both current and future—to join this important event. Shareholders are encouraged to send in questions in advance to participate in the discussion.

For more information about the teleconference and registration details, please visit [company website] or contact:

Media Contact:

Fifty 1 Labs, Inc.

Email:

For more information, please visit .

About Fifty 1 Labs, Inc.

Consumer Automotive Finance, Inc. (OTCPK: CAFI), soon to be renamed Fifty 1 Labs, Inc., is a publicly traded company focused on sports supplementation, fitness equipment, and holistic wellness. The company operates four key subsidiaries: 51, LLC, which specializes in sports supplements; The Quickness, which offers patented athletic training equipment; Astound NMN, a leader in anti-aging and DNA repair supplements; and Drago Knives, patented knife throwing technology. Fifty 1 Labs, Inc. is also actively pursuing strategic acquisitions to expand its portfolio and drive sustainable growth.

Safe Harbor Statement:

The information provided in this release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Identifiable by words such as "may," "will," "should," "plans," "expects," "anticipates," "continue," "estimate," "project," "intend," and similar expressions, these statements may also be made in written or oral form in the company's filings with the U.S. Securities and Exchange Commission, OTC Markets, press releases, other written materials, or in oral statements made by its officers, directors, or employees to third parties. There can be no assurance that such statements will prove to be accurate. The company cautions that these forward-looking statements are further qualified by other factors including, but not limited to, those set forth in the company's Disclosure Statements. Forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from those projected or anticipated. These risks and uncertainties include, but are not limited to, general economic and business conditions, effects of continued geopolitical unrest and regional conflicts, competition, changes in technology and methods of marketing, delays in completing various engineering and manufacturing programs, changes in customer order patterns, changes in product mix, continued success in technological advances and delivering technological innovations, shortages in components, production delays due to performance quality issues with outsourced components, and various other factors beyond the company's control. The company does not undertake any obligation to update publicly or to revise any statements in this release, whether as a result of new information, future events, or otherwise.

Investor Relations Contact:

Investor Relations

877-814-4188

Wire Service Contact:

IBN

Austin, Texas



512.354.7000 Office



EN
27/02/2025

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on CONSUMER AUTOMOTIVE FIN INC

 PRESS RELEASE

Fifty 1 Labs, Inc. and The Gates Foundation Lead Largest-Ever Sickle C...

Fifty 1 Labs, Inc. and The Gates Foundation Lead Largest-Ever Sickle Cell Disease Study, Unlocking Pathways for Gene-Based and Repurposed Therapies Landmark AI-driven analysis backed by The Gates Foundation sets stage for transformative treatments in one of the world's most underserved diseases VANCOUVER, British Columbia, Aug. 14, 2025 (GLOBE NEWSWIRE) -- via IBN -- Fifty1 AI Labs, Inc. (), a leader in AI-powered drug repurposing and precision medicine, today announced the completion of the largest and most comprehensive study of Sickle Cell Disease (SCD) ever undertaken. Leveraging a ...

 PRESS RELEASE

Fifty1 Labs, Inc. and BioSpark AI Unlock 2,000+ Real-World Treatment P...

Fifty1 Labs, Inc. and BioSpark AI Unlock 2,000+ Real-World Treatment Pathways to Accelerate Functional Medicine Innovation Strategic partnership and planned acquisition position Fifty1 Labs to dominate AI-driven drug repurposing and wellness therapeutics at scale VANCOUVER, British Columbia and PALO ALTO, Calif., Aug. 12, 2025 (GLOBE NEWSWIRE) -- via IBN --  Fifty1 AI Labs, a subsidiary of Fifty 1 Labs, Inc. (), together with its commercial partner BioSpark AI Technologies Inc., is announcing a major milestone in its AI-driven drug repurposing and functional medicine initiative. The joi...

 PRESS RELEASE

Fifty 1 Labs, Inc. Hosts Successful Virtual Shareholder Teleconference...

Fifty 1 Labs, Inc. Hosts Successful Virtual Shareholder Teleconference, Showcasing AI-Driven Functional Medicine Strategy and World-Class Leadership SEATTLE, July 29, 2025 (GLOBE NEWSWIRE) -- via IBN -- Fifty 1 Labs, Inc. (), a pioneer in AI-powered health and wellness solutions, successfully hosted its virtual shareholder teleconference on Monday, July 28, 2025, at 12:00 PM EST via X (formerly Twitter). The event drew significant engagement from shareholders and stakeholders, providing a comprehensive overview of the company's transformative growth strategy through its subsidiary, Fifty ...

 PRESS RELEASE

Fifty 1 Labs, Inc. to Host Virtual Shareholder Teleconference Featurin...

Fifty 1 Labs, Inc. to Host Virtual Shareholder Teleconference Featuring World-Class Leadership Team, including Dr. James Orbinski, who received the Nobel Peace Prize on Behalf of Médecins Sans Frontières SEATTLE, July 28, 2025 (GLOBE NEWSWIRE) -- Fifty 1 Labs, Inc. (), a leader in AI-powered health and wellness solutions, today announced it will host a virtual shareholder teleconference on Monday, July 28, 2025, at 12:00 PM EST. The event will be broadcast on X (formerly Twitter), featuring Nobel Peace Prize recipient Dr. James Orbinski, who accepted the 1999 Nobel Peace Prize on behalf o...

 PRESS RELEASE

Fifty 1 Labs, Inc. (FITY) Sparks AI Breakthrough in Drug Repurposing: ...

Fifty 1 Labs, Inc. (FITY) Sparks AI Breakthrough in Drug Repurposing: Subsidiary Fifty1 AI Labs Announces Strategic Partnership with Intent to Acquire BioSpark AI Technologies SEATTLE, July 17, 2025 (GLOBE NEWSWIRE) -- via IBN -- Fifty1 AI Labs, LLC, an innovative subsidiary of Fifty 1 Labs, Inc. (), is thrilled to announce a strategic partnership with an intent to acquire BioSpark AI Technologies Inc., a Vancouver-based pioneer in advanced AI and large language model (LLM) technologies. Revealed today, this alliance is set to transform drug repurposing by leveraging cutting-edge AI to un...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch